Anavex Life Sciences Corp (AVXL)

[sokol]

Yes. The AVXL information presented at CATD 2017 is helpful to design the AVXL 2-73 clinical trial going forward. Ariana was hired to focus on the best responders, which it seems are those with mild Alzheimer's. If a statistically significant number of mild Alzheimer's patients respond to treatment in the next phase, the drug will be approved. If it is approved, AVXL 2-73 will be prescribed, perhaps off label, for all Alzheimer's patients if it is perceived to improve sleep and mood. Sleep and mood is a major problem in Alzheimer's patients. I say all of this too because there is not much of anything currently available to treat Alzheimer's patients. No one at this point knows whether future mild Alzheimer's patients will respond positively or negatively compared to a placebo. Therefore, anyone that professes to predict one way or another is simply guessing. I am very long -- have been for a long time. I hope AVXL 2-73 is a success.